Shares of Inventiva S.A. (NASDAQ:IVA - Get Free Report) rose 0.8% on Tuesday . The stock traded as high as $3.67 and last traded at $3.65. Approximately 8,903 shares were traded during trading, a decline of 86% from the average daily volume of 64,692 shares. The stock had previously closed at $3.62.
Analyst Upgrades and Downgrades
A number of analysts have weighed in on the stock. Guggenheim cut their price objective on shares of Inventiva from $12.00 to $9.00 and set a "buy" rating on the stock in a report on Friday, April 4th. HC Wainwright reiterated a "buy" rating and set a $13.00 target price on shares of Inventiva in a research report on Friday, March 28th. Finally, TD Cowen began coverage on Inventiva in a research report on Friday, February 21st. They issued a "buy" rating and a $10.00 target price for the company. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $10.40.
View Our Latest Analysis on Inventiva
Inventiva Trading Down 3.4%
The business has a fifty day simple moving average of $3.41 and a 200 day simple moving average of $2.86.
Institutional Trading of Inventiva
An institutional investor recently bought a new position in Inventiva stock. Wealth Enhancement Advisory Services LLC acquired a new position in shares of Inventiva S.A. (NASDAQ:IVA - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 10,715 shares of the company's stock, valued at approximately $32,000. 19.06% of the stock is owned by hedge funds and other institutional investors.
Inventiva Company Profile
(
Get Free Report)
Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.
Featured Articles
Before you consider Inventiva, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inventiva wasn't on the list.
While Inventiva currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
